

**INCA Full Members**

- AMEND, **UK**
- APOZ, **Bulgaria**
- APTED, **France**
- Carcinoid Cancer Foundation, **USA**
- CarciNor, **Norway**
- Caring for Carcinoid, **USA**
- CARPA, **Sweden**
- CNETS, **Canada**
- CNETS, **Singapore**
- I.A.NET, **Italy**
- NET Patient Foundation, **UK**
- Netzwerk Neuroendokrine Tumoren, **Germany**
- Netpa, **Denmark**
- PanCAN Japan, **Japan**
- Pheo Paratroopers, **USA**
- The Unicorn Foundation, **Australia**
- The Unicorn Foundation, **New Zealand**
- VZW NET & MEN Kanker, **Belgium**



For more information:  
[www.netcancerday.org](http://www.netcancerday.org)

 [www.facebook.com/NETCANCERDAY](http://www.facebook.com/NETCANCERDAY)

 [www.twitter.com/NETCANCERDAY](http://www.twitter.com/NETCANCERDAY)

 [www.youtube.com/user/NETCANCERDAY](http://www.youtube.com/user/NETCANCERDAY)

**INCA** International  
Neuroendocrine  
Cancer Alliance

The Global Voice  
for NET Patients



## Uniting NET groups from around the world

The International Neuroendocrine Cancer Alliance (INCA) has committed to being the **global voice** for neuroendocrine cancer patients. Envisioning a world where all neuroendocrine cancer patients get a timely diagnosis, the best care and ultimately a cure, INCA's core mission is to **raise awareness** of neuroendocrine cancers.

The Alliance currently has **18 Full Members** – NET patient groups and advocacy organizations from **Asia, Australia, Europe, and North America**.

*“It is the passion to change things for the betterment of neuroendocrine cancer patients that drives us forward as a deeply committed team, to unite patient advocates from around the globe in this effort.”*

*INCA Team*



## Empowering patients

Encouraging early diagnosis by working collaboratively with the healthcare community and the public, the Alliance also recognizes universal access to high-quality **multidisciplinary care** and the dissemination of accurate and user-friendly information about neuroendocrine cancer as its top priorities.

INCA serves as a global platform to support existing and new patient-focused neuroendocrine groups and advocacy organizations from around the world. By maximizing the capacity of its current members and actively reaching out to new ones, INCA encourages sharing **best practices** and experience, which is crucial in the context of rare cancers.

As a network of patient advocacy organizations, INCA is a **resource for NET patients**, especially newly diagnosed patients, to find support groups in their countries and access other patients “on the journey”. Informed patients are better collaborators, since they can be active participants in the disease management process.

## Facilitating global action

In its capacity of a global patient-driven organization whose core mission is raising awareness, INCA works towards providing more attention for the rare disease space, supporting policies that improve research funding, insurance coverage, etc.

**November 10** has been promoted as Worldwide NET Cancer Awareness Day, to secure a greater voice for NET patients by joining efforts globally to engage people in various awareness-raising and educational activities.

In 2014, nearly **2,000 patients** from **12 countries** completed the **first-ever global NET patient survey** – a collaborative effort between INCA and Novartis. Its goal was to increase understanding of the experiences, needs and challenges of NET patients, and provide insights and learnings between countries and regions to **advance NET care** on a global level. The first global NET patient survey showed a substantial NET-related burden and identified areas for improvement to enhance patient care.

The global NET patient survey results are captured in a number of abstracts, presented at medical meetings and published in medical journals.

**For more information:**  
[www.netcancerday.org](http://www.netcancerday.org)

**INCA** International Neuroendocrine Cancer Alliance